Cargando…

Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review

The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ying-ying, Chen, Tao, Shen, Dan, Zhang, Wei-yun, Wang, Chang-guo, Jiang, Jun-hong, Zeng, Da-xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783257/
https://www.ncbi.nlm.nih.gov/pubmed/31847652
http://dx.doi.org/10.1177/0300060519887276
_version_ 1783632077744242688
author Liu, Ying-ying
Chen, Tao
Shen, Dan
Zhang, Wei-yun
Wang, Chang-guo
Jiang, Jun-hong
Zeng, Da-xiong
author_facet Liu, Ying-ying
Chen, Tao
Shen, Dan
Zhang, Wei-yun
Wang, Chang-guo
Jiang, Jun-hong
Zeng, Da-xiong
author_sort Liu, Ying-ying
collection PubMed
description The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and recent studies have also reported its successful use in non-SCLC; however, its efficacy in SCLC remains unclear. In this study, we used apatinib as salvage therapy for chemotherapy-refractory SCLC. Five male patients with advanced SCLC were administered oral apatinib (250 mg/day) as 2nd- to 4th-line treatment. One patient showed a partial response to apatinib, one showed stable disease, and three patients showed progressive disease. The progression-free survival durations in the patients with stable disease and partial response were 1.5 and 3 months, respectively. Only three patients showed adverse effects, including mild hypertension, vomiting, and hand–foot syndrome, respectively, all of which were manageable. Apatinib might thus be a salvage option in patients with advanced SCLC after chemotherapy.
format Online
Article
Text
id pubmed-7783257
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-77832572021-01-13 Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review Liu, Ying-ying Chen, Tao Shen, Dan Zhang, Wei-yun Wang, Chang-guo Jiang, Jun-hong Zeng, Da-xiong J Int Med Res Case Report The therapeutic regimen for small cell lung cancer (SCLC) has changed little in the past several decades. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase. Apatinib has demonstrated efficacy against advanced gastric cancer and breast cancer, and recent studies have also reported its successful use in non-SCLC; however, its efficacy in SCLC remains unclear. In this study, we used apatinib as salvage therapy for chemotherapy-refractory SCLC. Five male patients with advanced SCLC were administered oral apatinib (250 mg/day) as 2nd- to 4th-line treatment. One patient showed a partial response to apatinib, one showed stable disease, and three patients showed progressive disease. The progression-free survival durations in the patients with stable disease and partial response were 1.5 and 3 months, respectively. Only three patients showed adverse effects, including mild hypertension, vomiting, and hand–foot syndrome, respectively, all of which were manageable. Apatinib might thus be a salvage option in patients with advanced SCLC after chemotherapy. SAGE Publications 2019-12-18 /pmc/articles/PMC7783257/ /pubmed/31847652 http://dx.doi.org/10.1177/0300060519887276 Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Liu, Ying-ying
Chen, Tao
Shen, Dan
Zhang, Wei-yun
Wang, Chang-guo
Jiang, Jun-hong
Zeng, Da-xiong
Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
title Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
title_full Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
title_fullStr Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
title_full_unstemmed Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
title_short Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
title_sort low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783257/
https://www.ncbi.nlm.nih.gov/pubmed/31847652
http://dx.doi.org/10.1177/0300060519887276
work_keys_str_mv AT liuyingying lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview
AT chentao lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview
AT shendan lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview
AT zhangweiyun lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview
AT wangchangguo lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview
AT jiangjunhong lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview
AT zengdaxiong lowdoseapatinibmonotherapyinadvancedchemotherapyrefractorysmallcelllungcanceracaseseriesandliteraturereview